Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer

被引：8
|
作者：
Lim, J. U. [1 ]
机构：
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Pulm Allergy & Crit Care Med,Yeouido St Marys, Seoul, South Korea
来源：
CLINICAL ONCOLOGY | 2021年 / 33卷 / 10期
关键词：
Chemotherapy; lung cancer; osimertinib; progression; resistance; 3RD-GENERATION EGFR INHIBITORS; TYROSINE KINASE INHIBITORS; C797S MUTATION; OPEN-LABEL; ADENOCARCINOMA HISTOLOGY; ACQUIRED-RESISTANCE; GROWTH; MULTICENTER; PROGRESSION; AZD9291;
D O I：
10.1016/j.clon.2021.07.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Osimertinib is used as a first-line treatment for metastatic non-small cell lung cancer with positive epidermal growth factor receptor mutations based on the results of the FLAURA trial. However, as with any other epidermal growth factor receptor tyrosine kinase inhibitor, resistance also develops for osimertinib. Various genetic aberrations associated with the molecular heterogeneity of cancer cells contribute to osimertinib resistance. It is also important to choose an appropriate subsequent treatment for osimertinib-resistant non-small cell lung cancer. In this overview, we discuss the underlying mechanisms of osimertinib resistance and the efficacy of possible subsequent treatment measures. (c) 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：619 / 626
页数：8
相关论文
共 50 条
  • [1] Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between
    Passaro, Antonio
    Malapelle, Umberto
    Attili, Ilaria
    de Marinis, Filippo
    [J]. CANCER, 2020, 126 (11) : 2594 - 2596
  • [2] Darolutamide reverses osimertinib resistance in non-small cell lung cancer
    Schmitz, John C.
    Zhang, Guojing
    Liu, Zhentao
    Huang, Yufei
    Sica, Gabriel
    Sun, Shi-Yong
    Owonikoko, Taofeek K.
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [3] Development of metabolic-targeting therapy for overcoming resistance to osimertinib in non-small cell lung cancer cells
    Serizawa, Masakuni
    Umehara, Rina
    Ohshima, Keiichi
    Urakami, Kenichi
    Nagashima, Takeshi
    Yamaguchi, Ken
    Kaira, Kyoichi
    Takahashi, Toshiaki
    Kusuhara, Masatoshi
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients
    Uy, Natalie F.
    Tratt, Micah
    Eaton, Keith D.
    Santana-Davila, Rafael
    Baik, Christina S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
    Tang, Zheng-Hai
    Lu, Jin-Jian
    [J]. CANCER LETTERS, 2018, 420 : 242 - 246
  • [6] Osimertinib for the treatment of non-small cell lung cancer
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (02) : 225 - 231
  • [7] Clinical Outcomes of Various Resistance Mechanisms of Osimertinib in Chinese Advanced Non-Small Cell Lung Cancer Patients
    Xing, P.
    Mu, Y.
    Wang, S.
    Ma, D.
    Lin, J.
    Liu, H.
    Han-Zhang, H.
    Lizaso, A.
    Xiang, J.
    Mao, X.
    Hao, X.
    Li, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S396 - S396
  • [8] Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer
    Iwafuchi, Yoichi
    Saito, Isao
    Narita, Ichiei
    [J]. THERAPEUTIC APHERESIS AND DIALYSIS, 2017, 21 (04) : 416 - 417
  • [9] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    [J]. British Journal of Cancer, 2019, 121 : 725 - 737
  • [10] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    [J]. CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
12345